5:11 PM
 | 
Feb 06, 2012
 |  BC Extra  |  Clinical News

ChemoCentryx, GSK discontinue ChemR23 antagonist

ChemoCentryx Inc. (Mountain View, Calif.) said it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will discontinue development of CCX832 and its two backup compounds. ChemoCentryx said the decision was based on unblinded data from a Phase I trial of the oral small...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >